Table 6.
Summary of first-line studies in older patients.
| Reference | Treatment | n | Age [Years] | ORR [%] | Median PFS [Months] | Median OS [Months] |
|---|---|---|---|---|---|---|
| E-TRAB study | Trabectedin | 69 | Median: 78 | 23.2 (DCR) | 2.5 | 11.2 |
| Younger et al. [33] | Doxorubicin-based chemotherapies | 348 | >65 | 14.9 | 3.5 | 10.8 |
| Yousaf et al. [34] | Doxorubicin or others | 120 | >65 | 20 | n.e. | 6.5 |
| Mir et al. [31] | Cyclophosphamide | 27 | ≥65 | 27 | 6.8 | n.e. |
| Grosso et al. [32] | Trabectedin | 24 | ≥80 | 62 (DCR) |
4 | 9 |
| Hartmann et al. [12] | Trofosfamide | 80 | ≥60 | 6.6 | 2.8 | 12.3 |
| Grünwald et al. [11] | Pazopanib | 81 | ≥60 | n.e. | 4.4 | 12.3 |
| Jones et al. [35,36] | Trabectedin | 94 | >65 | 9 | 4.9 | 15.1 |
ORR—overall response rate; DCR—disease control rate; PFS—progression-free survival; OS—overall survival; n.e.—not evaluated.